Current prognostic and predictive factors in follicular lymphoma
- 14 October 2017
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (2) , 209-227
Abstract
Follicular lymphoma (FL) is generally considered an indolent disorder. With modern day treatments, long remissions are often achieved both in the front-line and relapsed setting. However, a subset of patients has a more aggressive course and a worse outcome. Their identification is the main purpose of modern day prognostic tools. In this review, we attempt to summarize the evidence concerning prognostic and predictive factors in FL, including (1) pre-treatment factors, from baseline clinical characteristics and imaging tests to histological grade, the microenvironment and genomic abnormalities; (2) post-treatment factors, i.e., depth of response, measured both by imaging tests and minimal residual disease; (3) factors at relapse and duration of response; and (4) prognostic factors in histological transformation. We conclude that, despite the existence of numerous tools, the availability of some of them is still limited; they generally suffer from notable downsides, and most have unproven predictive value, thus having scarce bearing on the choice of regimen at present. However, with the technological and scientific developments of the last few years, the potential for these prognostic factors is promising, particularly in combination, which will probably, in time, help guide therapeutic decisions.Keywords
This publication has 147 references indexed in Scilit:
- Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphomaBlood, 2014
- Clinical implications and prognostic role of minimal residual disease detection in follicular lymphomaTherapeutic Advances in Hematology, 2013
- Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practicesAnnals of Oncology, 2012
- Pathogenesis of follicular lymphomaJournal of Clinical Investigation, 2012
- Positron Emission Tomographic Scans in Lymphoma: Convention and ControversyMayo Clinic Proceedings, 2012
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- Randomized Clinical Trials With Biomarkers: Design IssuesJNCI: Journal of the National Cancer Institute, 2010
- Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterationsBlood, 2009
- The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survivalBlood, 2008
- A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-PrednisoneClinical Cancer Research, 2007